This is also supported by our dynamical analysis of CML time course data, which allows the identification of patients at high risk of molecular recurrence presenting with substantially increasing BCR-ABL1 levels after TKI dose reduction but performs insufficiently to discriminate patients presenting with no or a mild increase of BCR-ABL1 levels. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.